NDC 39822-0412-06 - Tobramycin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 39822-0412
- Requested NDC
- 39822-0412-06
- Package NDCs from labels
- 39822-0412-6, 39822-0412-1, 39822-0412-06
- Manufacturer
- XGen Pharmaceuticals DJB, Inc.
- Effective date
- 2025-10-08
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Tobramycin for Injection USP, 1.2 gm | XGen Pharmaceuticals DJB, Inc. | 2025-10-08 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 39822-0412-1 | Tobramycin | 1 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 1 | 27 | |
| 39822-0412-1 | Tobramycin | 30 mL in 1 VIAL | INJECTION, POWDER, LYOPHILIZED, | 30 | 27 | |
| 39822-0412-6 | Tobramycin | 6 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 6 | 27 | |
| 39822-0412-6 | Tobramycin | 30 mL in 1 VIAL | INJECTION, POWDER, LYOPHILIZED, | 30 | 27 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 39822-0412 | TOBRAMYCIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [XGEN PHARMACEUTICALS DJB, INC.] | 26 | Current NDC, Legacy NDC, 4 package rows | 20230328_a384641c-04e3-4ab5-b152-7408cd07b64d.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 39822-0412-1 | EA - Each | 39822-0412 | 3f999960-0cf0-4181-b285-b2112146976a | 1 | 2012-07-24 |
| 39822-0412-6 | EA - Each | 39822-0412 | 76dcde81-f11f-4a94-b41b-7aa8c6a72a29 | 1 | 2013-02-11 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| TOBRAMYCIN SULFATE | ACTIVE INGREDIENT | HJT0RXD7JK | TOBRAMYCIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [X-GEN PHARMACEUTICALS, INC.] | 16 | |
| TOBRAMYCIN | ACTIVE MOIETY | VZ8RRZ51VK | TOBRAMYCIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [X-GEN PHARMACEUTICALS, INC.] | 16 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| TOBRAMYCIN | TOBRAMYCIN | Hospira, Inc. | c5a005b0-7b6f-4e30-df92-9a20b1ca66a1 | 2026-04-13 | Boxed warning, Warnings, Adverse reactions | 597823 HJT0RXD7JK |
| Tobramycin | TOBRAMYCIN | Xiromed LLC | 8b50d1b5-ea8a-5844-358a-493f1965c07f | 2026-02-23 | Boxed warning, Warnings, Adverse reactions | 597823 HJT0RXD7JK |
| tobramycin | TOBRAMYCIN | Slate Run Pharmaceuticals, LLC | ed254eec-10f4-425a-895b-66e325b7bf69 | 2026-02-10 | Boxed warning, Warnings, Adverse reactions | 597823 |
| Tobramycin | TOBRAMYCIN | XGen Pharmaceuticals DJB, Inc. | a384641c-04e3-4ab5-b152-7408cd07b64d | 2025-10-08 | Boxed warning, Warnings, Adverse reactions | ANDA065013 39822-0412-1 39822-0412-6 39822-0412 39822041206 597823 40a90656-9bc2-494b-e063-6294a90a04f2 a384641c-04e3-4ab5-b152-7408cd07b64d HJT0RXD7JK |
| Tobramycin | TOBRAMYCIN | Northstar Rx LLC | 55d09ffd-4f32-8aeb-3904-8a17db635e3a | 2025-09-23 | Boxed warning, Warnings, Adverse reactions | 597823 HJT0RXD7JK |
| TOBRAMYCIN | TOBRAMYCIN | Eugia US LLC | c37c251f-92e9-40f0-8b0c-00d42875d776 | 2024-07-06 | Boxed warning, Warnings, Adverse reactions | 597823 HJT0RXD7JK |
| Tobramycin | TOBRAMYCIN SULFATE | Fresenius Kabi USA, LLC | 9a5cecd6-aa65-42d2-b15a-06b4fcebcc0f | 2024-02-07 | Boxed warning, Warnings, Adverse reactions | 597823 HJT0RXD7JK |
| Tobramycin | TOBRAMYCIN SULFATE | Fresenius Kabi USA, LLC | d6dd9460-b030-479a-b3e3-03606e6fcad1 | 2024-02-05 | Boxed warning, Warnings, Adverse reactions | 597823 HJT0RXD7JK |
| Tobramycin | TOBRAMYCIN SULFATE | Fresenius Kabi USA, LLC | d62ff359-912b-4be1-9fc2-2dde8777eefb | 2024-01-15 | Boxed warning, Warnings, Adverse reactions | 597823 HJT0RXD7JK |
| Tobramycin | TOBRAMYCIN | Baxter Healthcare Corporation | a9897444-71f6-42af-9b71-4aa77829ade0 | 2023-03-15 | Boxed warning, Warnings, Adverse reactions | 597823 HJT0RXD7JK |
| Tobramycin | TOBRAMYCIN | Gland Pharma Limited | 645d34d9-275d-428e-863d-ae15ad009c44 | 2023-03-09 | Boxed warning, Warnings, Adverse reactions | 597823 HJT0RXD7JK |
| Tobramycin | TOBRAMYCIN | Gland Pharma Limited | 02b48684-168c-4cd9-8375-794206eff23e | 2023-02-27 | Boxed warning, Warnings, Adverse reactions | 597823 HJT0RXD7JK |
| Tobramycin | TOBRAMYCIN | Fosun Pharma USA Inc | c4751a4f-c9c1-60c5-e053-2995a90aeba9 | 2022-12-02 | Boxed warning, Warnings, Adverse reactions | 597823 HJT0RXD7JK |
| Tobramycin | TOBRAMYCIN | Mylan Institutional LLC | ac8134d9-a726-4508-b8b9-a536ef17243d | 2022-10-31 | Boxed warning, Warnings, Adverse reactions | 597823 HJT0RXD7JK |
| Tobramycin | TOBRAMYCIN | Gland Pharma Limited | 38219f34-4859-428f-9ec1-06ead7604211 | 2022-10-17 | Boxed warning, Warnings, Adverse reactions | 597823 HJT0RXD7JK |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.